FDA Approved: SYMFI — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved a supplemental application for SYMFI, the fixed-dose combination of efavirenz, lamivudine, and tenofovir disoproxil fumarate, from Viatris Spec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• SYMFI (EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for SYMFI (EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE)